Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126757681 | 12675768 | 1 | I | 20160815 | 0 | 20160822 | 20160822 | DIR | 41.00 | YR | F | N | 105.50000 | KG | 20160819 | N | PH | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126757681 | 12675768 | 1 | PS | INVOKANA | CANAGLIFLOZIN | 1 | Oral | D | D | 0 | 300 | MG | HS | ||||||
| 126757681 | 12675768 | 2 | SS | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | D | D | 0 | 1000 | MG | BID | ||||||
| 126757681 | 12675768 | 3 | SS | GLIPIZIDE. | GLIPIZIDE | 1 | Oral | 0 | 10 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126757681 | 12675768 | 1 | Type 2 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126757681 | 12675768 | LT |
| 126757681 | 12675768 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126757681 | 12675768 | Acidosis | |
| 126757681 | 12675768 | Blood glucose increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | CASEID | RPSR COD |
|---|---|---|
| 126757681 | 12675768 | HP |
Therapies reported
| no results found |